A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus
Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, copyright and Moderna to protect high-risk populations against respiratory syncytial virus (RSV).These vaccines employ the pre-fusion F (pre-F) protein as the immunogen.In this study, we explored an mRNA vaccine based on a modified pre-F Covers protein called LC2